Open-house rebate agreement for Sarilumab
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
48 / 100
Risk factors
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house rebate agreements for the medicinal product substance Sarilumab, ATC L04AC14.
- Supply contract for pharmaceutical products.
Show full summary
This is an open-house pharmaceutical supply arrangement for Sarilumab (ATC L04AC14) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2024-11-01 to 2026-10-31, with contract entry possible until 2026-09-05. Submission is allowed electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents. No contract value is stated.
Risks
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Sarilumab
Single lot for non-exclusive open-house rebate agreements concerning the pharmaceutical substance Sarilumab (ATC L04AC14). The lot is for supplies and is performance-related to Germany, specifically Bavaria (DE212).
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 557248-2024
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
48 / 100
Risk factors
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications